Clinical aspects of systemic and localized scleroderma by Hoogen, F.H.J. van den & Jong, E.M.G.J. de
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/21697
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
546
Clinical aspects of systemic and localized scleroderma
Frank H.J. van den Hoogen, MD, and Elke M.G.J. de Jong, MD
University Hospital Nijmegen, Nijmegen, the Netherlands
After the skin, the gastrointestinal tract is the most frequently affected organ in systemic 
sclerosis. Gastrointestinal symptoms already may be present early in the course of the 
disease and do not necessarily correlate with objective findings. Esophageal dysmotility 
is not specific for systemic sclerosis but occurs in other connective tissue diseases as 
well. Peripheral macrovascular disease was shown to be increased in patients with 
limited cutaneous sclerosis; signs of autonomic dysfunction were found in patients with 
the CREST (calcinosis, Raynaud's phenomenon; esophageal dysfunction, sclerodactyly, 
and telangiectasia) variant. Pulmonary involvement was shown to be moderately 
or severely decreased in 40% of a large cohort of scleroderma patients. In one 
study, no support was found for the association between pulmonary involvement and 
gastroesophageal reflux. Peripheral nerve involvement is often subclinical and might 
be associated with anti~U1~RNP and anti-topoisomerase I antibodies. Internal organs 
are seldomly affected in localized scleroderma. W hen occurring in childhood and 
involving an extremity, localized scleroderma can cause growth failure, resulting in 
long-term functional disability.
:
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Systemic sclerosis
Survival
The natural course of systemic sclerosis may vary 
widely. Some patients experience spontaneous remis­
sion, but the majority undergo progression of skin 
and internal organ involvement, leading to consider­
able morbidity and mortality. The cumulative survival 
rate has been shown to be as little as 30% at 12 years. 
Internal organ involvement, presence of antitopoiso- 
merase autoantibodies, and diffuse skin involvement 
are known to adversely affect outcome, Because renal 
crisis can now be treated successfully in most cases 
with angiotensin-converting enzyme (ACE) inhibitors, 
the leading cause of death in patients with systemic 
sclerosis is cardiopulmonary disease. The improved out­
come of patients with renal crisis was reviewed by Steen 
[1], An increase in both incidence and mortality during 
the past decades may be the result of improved case 
detection rather than a true increase, as discussed by 
Medsger [2].
In a nationwide epidemiologic study from Iceland, a low 
incidence of systemic sclerosis (3.8 per million) and a 
high proportion of patients with limited cutaneous in­
volvement was found, which might account for the ob­
served 10-year survival rate of 81% (31.
Malignancy
In the past, several reports emphasized the coincidence 
of systemic sclerosis and malignancy, especially cancer 
of the lung and breast. Patients with older age at di­
agnosis and who test positive for anti-topoisomerase I 
antibodies were found to be at particular risk for de­
veloping cancer [4,5]. A case of ductal carcinoma of the
prostate was reported in a patient with rapidly progres­
sive systemic sclerosis [6]. The possible pathogenetic in­
terrelationships between systemic sclerosis and malig­
nancy are as yet unknown.
Gastrointestinal involvement
After the skin, the gastrointestinal tract is the second 
most commonly affected organ in systemic sclerosis. 
Gastroesophageal reflux, small-bowel bacterial over­
growth, malnutrition, and intestinal pseudoobstaiction 
are the main clinical manifestations. An excellent re­
view of the literature concerning pathophysiology, clin­
ical features, diagnostic procedures, and possible treat­
ments of gastrointestinal involvement in systemic scle­
rosis was provided by Sjogren [7**], who emphasized 
that many patients with systemic sclerosis and without 
gastrointestinal symptoms do have gastrointestinal ab­
normalities on careful examination. The author also hy­
pothesized that progressive gastrointestinal dysfunction 
is the result of an orderly series of steps, First, the earli­
est lesions could be induced by neural dysfunction, ei­
ther due to arteriolar changes in the vasa nervorum or to 
compression of nerve fibers by collagen deposits. The 
next lesion is smooth-muscle atrophy, superimposed on 
the already existing neural dysfunction. Finally, muscle 
fibrosis occurs, which is essentially irreversible.
In a prospective survey, gastrointestinal manifestations 
of systemic sclerosis were found in 82% of 262 pa­
tients [8**1 The most common findings were esophageal 
dysmotility, lower esophageal sphincter laxity, bacte­
rial overgrowth, and wide-mouth diverticula. No sig­
nificant correlations were found between gastrointesti­
nal involvement and gender, age at diagnosis of sys­
temic sclerosis, or subtype of disease (diffuse-limited).
Abbreviations
ACE—angiotensin-converting enzyme; CREST—calcinosis, Raynaud's phenomenon, esophageal dysfunction, 
sclerodactyly, and telangiectasia; " mTc-DPTA—technetium-labeled dlethylene-triamine pentacetate.
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It was found that upper-gastrointestinal symptoms de­
velop early in the course of the disease and do not nec­
essarily correlate with objective findings.
In an Italian study [91, the prevalence and pattern of 
esophageal motility disorders was examined in 150 pa­
tients with systemic sclerosis and other rheumatic dis­
eases such as rheumatoid arthritis, systemic lupus ery­
thematosus, poly- and dermatomyositis, and unclassi­
fied connective tissue diseases. Although motility dis­
orders of the esophageal body and lower esophageal 
sphincter statistically occur more frequently in systemic 
sclerosis, they are not specific to systemic sclerosis. The 
lack of consistent correlations between a specific pattern 
of esophageal dysfunction and Raynaud’s phenomenon 
suggests that esophageal dysfunction and Raynaud\s 
phenomenon may not have a common pathogenetic 
mechanism.
A rare but important condition associated with systemic 
sclerosis is small-bowel telangiectasia, as exemplified by 
the case of a 47-year-old woman with systemic sclerosis 
and excessive gastrointestinal bleeding due to multiple 
telangiectases throughout the whole small intestine [10],
Cardiovascular disease
Heart involvement in systemic sclerosis consists of peri­
carditis, congestive failure, and arrhythmias, and was re­
viewed by Clements and Fnrst [11], Also, a patient with 
limited scleroderma complicated by a pericardial effu­
sion sufficient to cause hemodynamic compromise was 
described recently [12],
Autonomic dysfunction was examined in nine patients 
with diffuse scleroderma and in eight with CREST (calci­
nosis , Raynaud's phenomenon, esophageal dysfunction, 
sderodactyly, and telangiectasia) syndrome; results of a 
short-term analysis of heart-rate variability in these pa­
tients were compared with those for healthy controls 
[131. An abnormal heart-rate variability was found in pa­
tients with CREST syndrome; these results differed sig­
nificantly from those of patients with diffuse cutaneous 
disease, suggesting that parasympathetic control of the 
heart rate is decreased in patients with CREST syndrome.
The prevalence of macrovascular disease was studied 
in a retrospective cohort of patients with limited sys­
temic sclerosis [14*]. Peripheral macrovascular disease 
occurred in 58% of the patients, compared with only 
3% of well-matched controls. Macrovascular disease oc­
curred mainly in the abdominal arteries and arteries 
of the lower extremities; no significant increase in the 
prevalence of coronary artery or cerebrovascular disease 
was observed. In the majority of patients, macrovas­
cular disease was symptomatic and required surgical 
intervention.
Microvaseular endothelial injury is a prominent feature 
in systemic sclerosis. In a study set: up to examine the 
significance of circulating levels of endothelin-1 in re­
lation to vascular damage and fibrosis, a relationship 
was found between circulating levels of endothelin-1 
and other markers of fibrosis and vascular damage such 
as angiotensin-converting enzyme and von Willebrand 
factor [15].
Hypotheses on the pathogenesis of Raynaud's phe­
nomenon, which occurs in up to 90% of patients 
with systemic sclerosis, were reviewed by Kahaleh
and Matucci-Cerinic [16*], who discussed the possi­
ble etiopathogenetic role of neuropeptides, which are 
found in abundance in human skin and are involved in 
the control of skin blood flow.
Serial nailfold capillary microscopy was performed in 
patients with primary Raynaud's phenomenon and sys­
temic sclerosis [17]. Gradually decreasing numbers of 
capillary loops and increasing numbers of widened and 
giant loops were found in the following conditions in 
die following order: primary Raynaud’s phenomenon, 
possible systemic sclerosis, and systemic sclerosis, sug­
gesting that these disorders are part of a continuing 
spectrum of Raynaud’s phenomenon,
Pulmonary involvement
Pulmonary involvement occurs in 60% to 80% of pa­
tients with systemic sclerosis, Clinical manifestations 
consist of dyspnea, pleurisy, pulmonary fibrosis, and 
pulmonary hypertension. Lung disease is associated 
with decreased survival To identify risk factors for de­
veloping severe restrictive lung disease and to deter­
mine the time of onset and rate of progression in pa­
tients with systemic sclerosis, Steen et cil, [18” 1 used the 
University of Pittsburgh Scleroderma Databank to group 
890 patients according to their lowest forced vital ca­
pacity value: greater than 75% predicted, 50% to 75% 
predicted, and less than 50% predicted. They also ana­
lyzed serial pulmonary function test results in patients 
with restrictive lung disease to assess the rate of deteri­
oration of lung volume over time. Only 13% of the pa­
tients appeared to have severe restrictive lung disease, 
with forced vital capacity less than or equal to 50% pre­
dicted; 27% had moderate restrictive lung disease, with 
a forced vital capacity of 50% to 75% predicted; and 60% 
of the patients had no or minimal restrictive lung disease 
(forced vital capacity ¿75%). Multiple logistic regression 
showed that black race, male gender, early disease, and 
primary cardiac involvement due to systemic sclerosis 
were the characteristics most frequently associated with 
severe lung disease. Of interest, scleroderma subtype 
(limited or diffuse) and anti-topoisomerase I antibody, 
which is known to be associated with poor prognosis, 
were not differentiating factors between moderate and 
severe restrictive disease.
Pulmonary function in systemic sclerosis may be the 
result of gastroesophageal reflux, most presumably by 
microaspiration of refluxed material into the lungs. 
The relationships between esophageal dysfunction, gas­
troesophageal reflux, and lung involvement in sys­
temic sclerosis were studied by Troshinshlcy et al 
[19*1, who grouped 39 patients according to the pres­
ence or absence of abnormal distal or proximal gastro­
esophageal acid reflux and the presence or absence 
of distal esophageal peristalsis. Esophageal manometry, 
dual-probe (distal and proximal) esophageal 24-hour 
pH measurements, and pulmonary function tests were 
performed in all patients. The results did not support 
an association between pulmonary function impairment 
and abnormal proximal or distal esophageal pH,
The value of the clearance rate of inhaled technetium- 
labeled diethylene-triamine pentacetate (^^Tc-DPTA) 
in detecting early pulmonary involvement was studied 
prospectively in 16 patients with systemic sclerosis with­
out pulmonary symptoms and chest radiography abnor-
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malities [20]. In six patients, an abnormal 99tnTC..;DPTA 
clearance was found, and in Five of these patients, it 
was associated with pathologic findings on high-resolu- 
tion computed tomography, suggestive of early intersti­
tial lung disease. This finding indicates that 99nrpc-DPTA 
lung scintigraphy may allow early detection of subclin- 
ical pulmonary involvement in systemic sclerosis.
The results of a study in which bronchoalveolar lavage 
findings were related to computed tomographic appear­
ance of fibrosing alveolitis in systemic sclerosis indicated 
that in systemic sclerosis, bronchoalveolar lavage neu­
trophilia is generally associated with extensive fibrotic 
disease, whereas bronchoalveolar lavage eosinophilia 
is often observed in less-advanced disease, especially 
when computed tomographic appearances suggest pul­
monary inflammation [21].
Features of small-airways dysfunction were observed in 
four of four patients with limited scleroderma and in 
three of seven patients with diffuse scleroderma [22], 
It was concluded that small-airways disease may be an 
early feature of systemic sclerosis, especially in patients 
with limited scleroderma, This conclusion was ques­
tioned [23], because the high incidence of small-airways 
disease found in this study differed from the findings of 
a previous study [24],
Several aspects of pulmonary hypertension as a com­
plication of connective tissue disease, particularly sys­
temic sclerosis, were addressed in an editorial [25]. In 
an open study, the same group of investigators reported 
improved exercise tolerance and quality of life in pa­
tients with severe pulmonary hypertension associated 
with systemic sclerosis (w « 3) and primary antiphos­
pholipid antibody syndrome (n  = 2) after treatment with 
continuous iloprost infusion [26], These results warrant 
confirmation in further controlled trials,
Renal involvement
Renal crisis, once the major cause of death in patients 
with systemic sclerosis, can be successfully treated with 
ACE inhibitors in the majority of patients. Discontinua­
tion of dialysis even after a prolonged period has been 
observed after treatment with ACE inhibitors. As pointed 
out by Steen [1], prompt diagnosis and early aggressive 
treatment of scleroderma renal crisis with ACE inhibitors 
are mandatory for an optimal outcome.
Molina et cil, [27] reported the development of renal 
crisis in a patient with systemic sclerosis sine scle­
roderma, who presented with symmetric polyarthritis. 
Scleroderma renal crisis, with malignant hypertension 
and cardiac and renal failure, was histologically con­
firmed. Anti-RNA polymerase III antibodies were pos­
itive. These autoantibodies are highly specific for sys­
temic sclerosis [28] and are associated with renal in­
volvement [29).
Nervous system
Signs and symptoms of neurologic involvement are rare 
in patients with systemic sclerosis, although subciinical 
peripheral nerve involvement has been demonstrated 
in a considerable proportion of patients [30]. A case of 
systemic sclerosis complicated by peripheral neuropa­
thy associated with vasculitic change on biopsy was 
described [31]. The possible contribution of anticardi-
olipin antibodies to vasculitis in this patient is briefly dis­
cussed. The same group of investigators described two 
patients with limited systemic sclerosis and mononeu­
ritis [32], Because both patients had severe digital is­
chemia, it was presumed that inflammatory blood vessel 
wall changes might have been an etioiogic factor in the 
neuropathy.
An association of anti-Ul-RNP and anti-topoisomerase 
I antibodies with neurologic manifestations was sug­
gested by Hietarinta et al[33]. They examined 31 scle­
roderma patients, 11 of whom had neurologic find­
ings such as trigeminal neuropathy and polyneuropa­
thy. Eight of these 11 patients had either anti-Ul-RNP 
or anti-topoisomerase I antibodies in their sera.
Autoantibody associations
The association of specific autoantibodies with the clin­
ical features and disease course of scleroderma was ex­
tensively reviewed by Wigley [34] in the November 1994 
issue of Current Opinion in Rheumatology.
In the past year, two studies reported on the clinical 
correlations of anticentromere antibodies. Although an­
ticentromere antibodies are associated with limited scle­
roderma, their occurrence in other autoimmune-medi- 
ated diseases is well known. In a study from Taiwan 
[35], anticentromere antibodies were found in patients 
with Sjogren's syndrome, systemic lupus erythematosus, 
rheumatoid arthritis, immune thrombocytopenic pur­
pura, and Graves’ disease. A retrospective survey of pa­
tients with anticentromere antibodies detected during 
routine antinuclear antibody testing [36] showed that 
in only 29% a diagnosis of systemic sclerosis could be
made,
Herrick et al. [37] found no support for an associa­
tion between anticardiolipin antibodies and severe is­
chemia in systemic sclerosis but confirmed the asso­
ciation between anticentromere antibodies and severe 
peripheral ischemia and found an association between 
anti-topoisomerase I antibodies and severe ischemia.
Localized scleroderma
Based on the morphologic features and distribution 
of skin lesions, localized scleroderma is classified into 
three subtypes: morphea, generalized morphea, and lin­
ear scleroderma, Localized scleroderma is rare, with le­
sions that are usually confined to the skin and under­
lying subcutaneous tissue. Internal organ involvement, 
such as occurs in systemic sclerosis, is seldom observed. 
The frequency, prognosis, and predictors of internal or­
gan involvement were studied in a group of 53 patients 
with morphea with or without linear scleroderma [38*], 
Systematic examination revealed internal involvement 
in 16 patients. The abnormalities found were mostly 
asymptomatic, consisting of esophageal dysfunction and 
slightly impaired carbon monoxide diffusion in the lung, 
After a median follow-up of 48 months, prognosis was 
not influenced by such involvement. Only two of these
16 patients, one of whom developed systemic sclero­
sis, had symptomatic and severe visceral disease. Pa­
rameters that were found to be associated with internal 
involvement were male gender, increasing number of 
skin lesions, and hypergammaglobulinemia at first ex­
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animation. This study emphasizes that localized sclero­
derma and systemic sclerosis behave as two different 
diseases and that routine screening for internal involve­
ment is not justified in asymptomatic patients with lo- 
ca 1 ized scleroderma.
Despite the low prevalence of visceral abnormalities in 
localized scleroderma, it can result in long-term func­
tional disability. This is especially true in linear sclero­
derma, which mainly occurs in childhood. Thirty cases 
of localized scleroderma in children were reported by 
Uziel et al. [39*]; five of 19 patients with linear sclero­
derma that involved an extremity had growth failure in 
that limb, and one patient required surgery. Growth fail­
ure resulted from the extension of fibrosis from the skin 
into subcutaneous tissue, muscle, and even bone, The 
authors also reviewed the literature concerning drug 
therapy in localized scleroderma. Although many drugs 
are advocated for use in localized scleroderma, none of 
these drugs have been proven effective. Clinical studies 
aimed toward evaluation of drug therapy are hampered 
by the lack of disease activity parameters. Clinical eval­
uation of the skin lesion was found to offer the only 
possibility for monitoring disease activity,
Treatment with oral prednisone (starting dose ranging 
from 0.5 to 1.0 mg/kg/d; duration of treatment for at 
least 6 weeks) in 17 patients with localized scleroderma 
resulted in complete disappearance of skin lesions in 
four patients [40]. A favorable effect on the disease 
course was observed in 13 other patients. Six patients 
experienced a relapse after treatment discontinuation. In 
another study, great improvement in skin sclerotic le­
sions and joint mobility was seen in one patient who 
was treated with the antiallergy drug tranilast [41]. Such 
findings should be critically examined, because in the 
majority of patients, localized scleroderma is a self-lim­
ited disease. It is preferable that the efficacy of any drug 
treatment be assessed in placebo-controlled trials.
The etiology of localized scleroderma is unknown, The 
resemblance of morphea to acrodermatitis chronica at­
rophicans has been the focus of a possible association 
of Borrelia burgdorferi with localized scleroderma. Sev­
eral studies of this association did not lead to unequiv­
ocal results. Wienecke et a l  [42*] analyzed skin biopsy 
specimens from 30 patients with localized scleroderma 
for the presence of B, burgdorferi using three different 
polymerase chain reaction systems for amplification of 
segments of borrelial genes. Borrelial DNA was not de­
tected in any of the biopsy specimens, a finding that 
does not support the concept of the presence of B. 
burgdorferi in active lesions of localized scleroderma. 
However, B. burgdorferi still may be present in early 
sclerotic lesions and initiate changes in connective tis­
sue that lead to morphea. It also may be possible that 
the positive association of localized scleroderma with B . 
burgdorferi is confined to endemic areas [431.
The occurrence of multiple morphea-like changes in 
a patient with eosinophilic fasciitis is rare, One such 
case was described by Castanet et a l  [44]. The patient 
also had antiphospholipid antibodies, neurologic symp­
toms, and livedo-like cutaneous lesions. The cooccur­
rence of either morphea or eosinophilic fasciitis and an­
tiphospholipid antibodies has never been reported in 
the literature before. Lipomembranous (membranocys- 
tic) changes in adipose tissue, known to occur in a nurn-
ber of diseases including discoid and systemic lupus ery­
thematosus, were reported in three patients with local­
ized scleroderma [45].
Scleroderma-like lesions and juvenile 
scleroderma
Castanet et a l [46] reported the case of a 74-year- 
old man with porphyria cutanea tarda, who presented 
with inflammatory sclerodermatous plaques and derma - 
tohelios of 2-years' existence. During repeated phle­
botomies, sclerodermatous lesions simultaneously im­
proved, with the reduction of urinary uroporphyrin and 
ferritin levels.
In children, mostly localized forms of scleroderma are 
seen, although systemic disease can occur. Approxi­
mately 3% of all scleroderma cases are juvenile [47], 
The prognosis, management, and current therapeutic 
options for scleroderma and scleroderma-like disorders 
in children recently were reviewed by Black [48],
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